Amlodipine/olmesartan - Hanlim PharmAlternative Names: Lodivikar
Latest Information Update: 14 Dec 2016
At a glance
- Originator Hanlim Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Nicotinic-acids; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Hypertension
Most Recent Events
- 01 Apr 2014 Phase-I clinical trials in Hypertension (In volunteers) in South Korea (PO) (NCT02955498)